ClinicalTrials.gg
Active, not recruitingNCT05677451Updated Oct 15, 2026

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

A Phase 3 interventional study of LOU064 (blinded) and placebo in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 49 sites in 17 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Oct 2, 20261 site added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
10th of 12
100 · median 347
Started
2023
with 2 others
Phase 3
9 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 10th largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 7th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

The purpose of this trial is:

  1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines
  2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment
  3. to collect safety data in this population for up to three years after the last dose of study treatment
Read the detailed description

This trial consists of 3 different periods:

  1. the "core period", which is randomized and double-blind, during which 2/3 participants will receive remibrutinib and 1/3 will receive placebo for 24 weeks. Total duration: approximately 32 weeks (10 site visits).
  2. an optional "open-label extension (OLE) period" proposed to all participants who completed 24 weeks of treatment of the "core period" and all scheduled assessments planned at week 24 visit . Depending on their CSU symptoms (as assessed by the doctor), participants will either receive remibrutinib for 24 weeks, or enter an observational treatment-free period for 1 year. If the CSU symptoms return during the observational period, the participants can switch to the treatment period at any time (decided by the doctor). At the end of the 24-week treatment period, if CSU is controlled, participants will enter the 1-year observational period, otherwise, they can continue with another cycle of 24-week remibrutinib treatment. The number of remibrutinib treatment or observational cycles will be limited to 6 times each. Total duration: from 1 year to approximately 3 years, and number of visits: from 3 to 15 (depending on the CSU symptoms).
  3. an optional "long-term treatment-free follow-up period" proposed to all participants who completed at least 4 months treatment in the "OLE period". No treatment will be given. Duration: 3 years with 1 site visit and up to 4 phone call follow-up visits.

The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • BTK inhibitor
  • Chronic spontaneous urticaria
  • Urticaria activity score
  • Hives severity score
  • Itch severity score
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male and female adolescent participants aged >= 12 to \< 18 years of age at the time of signing the
  • CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
  • Diagnosis of CSU inadequately controlled by second-generation H1-AH at the time of randomization defined as:
  • The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of second-generation H1-AH during this time period according to local treatment guidelines
  • UAS7 score (range 0 - 42) >= 16, ISS7 score (range 0 - 21) >= 6 and HSS7 score (range 0 - 21) >= 6 during the 7 days prior to randomization (Day 1)
  • Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)

Key Exclusion criteria:

  • Previous use of remibrutinib or other BTK inhibitors
  • Significant bleeding risk or coagulation disorders
  • History of gastrointestinal bleeding
  • Requirement for anti- medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited
  • History or current hepatic disease
  • Evidence of cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
  • History of to any of the study drugs or its or to drugs of similar chemical classes
  • Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
  • Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
  • Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Arm 1: LOU064 (blinded)

    LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks.

    Drug: LOU064 (blinded)

  • Placebo comparator
    Arm 2: LOU064 placebo (blinded)

    LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2)

    Drug: placebo

Interventions

  • LOU064 (blinded) active treatment

    Also known as: remibrutinib

  • Drugplacebo

    matching active drug

06

What researchers measure

Primary outcomes

  1. Change from baseline in UAS7

    The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0. Negative change from baseline indicates improvement.

    Time frame: Baseline, week 12

  2. Change fron baseline in ISS7

    Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  3. Change from baseline in HSS7

    Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (\>12 hives/12 hours). Negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Cmax of remibrutinib

    The maximum (peak) observed blood drug concentration after single dose administration

    Time frame: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

  2. Tmax of remibrutinib

    The time to reach maximum (peak) blood drug concentration after single dose administration

    Time frame: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

  3. AUClast of remibrutinib

    The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time

    Time frame: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

  4. Absolute change from baseline in ISS7

    Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement.

    Time frame: Baseline - Week 12

  5. Absolute change from baseline in HSS7

    Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (\>12 hives/12 hours). Negative change from baseline indicates improvement.

    Time frame: Baseline - Week 12

  6. Achievement of UAS7 ≤ 6 (yes/no)

    Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

    Time frame: Week 12 and over time

  7. Achievement of UAS7 = 0 (yes/no)

    Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

    Time frame: Week 12 and over time

  8. Absolute change from baseline in CDLQI score

    The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

    Time frame: Week 12

  9. Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response

    Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity.

    Time frame: baseline - Week 12

  10. Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period

    To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study.

    Time frame: 28 weeks

  11. Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period

    To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study.

    Time frame: 3 years

07

Study locations

49 sites
  • Kern Research
    Bakersfield, California 93301, United States
  • Allergy and Asthma Medical Group and Research Center
    San Diego, California 92123, United States
  • Pediatric Dermatology of Miami at the Pediatric CoE
    Miami, Florida 33156, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Endeavor Health
    Glenview, Illinois 60077, United States
  • Allergy and Asthma Specialist P S C
    Owensboro, Kentucky 42301, United States
  • Toledo Institute of Clinical Research
    Toledo, Ohio 43617, United States
  • Allergy Asthma and Clinical Research
    Oklahoma City, Oklahoma 73120, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • RFSA Dermatology
    San Antonio, Texas 78213, United States
  • Allergy Associates of Utah
    Sandy City, Utah 84093, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1414AIF, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    San Miguel de Tucumán, T4000AXL, Argentina
  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 8420383, Chile
  • Novartis Investigative Site
    Guangzhou, Guangdong 510091, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Beijing, 100069, China
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Hong Kong, Hong Kong 999077, Hong Kong
  • Novartis Investigative Site
    Florence, FI 50139, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 8078556, Japan
  • Novartis Investigative Site
    Kamimashi-gun, Kumamoto 8613106, Japan
  • Novartis Investigative Site
    Sakai, Osaka 5938324, Japan
  • Novartis Investigative Site
    Izumo, Shimane 6938501, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 1738610, Japan
  • Novartis Investigative Site
    Kuching, Sarawak 93586, Malaysia
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Lodz, 90-436, Poland
  • Novartis Investigative Site
    Pretoria, Gauteng 0181, South Africa
  • Novartis Investigative Site
    Cape Town, 7925, South Africa
  • Novartis Investigative Site
    Esplugues, Barcelona 08950, Spain
  • Novartis Investigative Site
    Valencia, 46014, Spain
  • Novartis Investigative Site
    Songkhla, Hat Yai 90110, Thailand
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Istanbul, Fatih 34093, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Sihhiye Altindag 06230, Turkey (Türkiye)
  • Novartis Investigative Site
    Adana, 01330, Turkey (Türkiye)
  • Novartis Investigative Site
    Peterborough, Cambridgeshire PE3 9GZ, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Nov 2026, 39 months after the start.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's planned 39 months is above that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2022
First posted
Jan 10, 2023
StartActual
Jul 11, 2023
Primary completionEst.
Nov 3, 2026
CompletionEst.
Mar 30, 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 2 sites removed
Show site
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Show 2 removed
  • Novartis Investigative Site · Hong Kong, Hong Kong
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Oct 2, 2026
Show all 2 updates
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 2, 2026
    1 site added, 2 sites removed
    Show site
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 2 removed
    • Novartis Investigative Site · Hong Kong, Hong Kong
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05677451
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Jul 11, 2023
Primary completion
Nov 3, 2026 (estimated)
Completion
Mar 30, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion